Skip to main content
NVDA+0.52%AAPL-0.70%GOOGL-1.40%MSFT-0.90%AMZN-1.60%TSM-1.08%SPCX-2.59%META+0.01%AVGO-1.47%TSLA+0.48%SKHY-1.20%BRK-B+0.03%LLY+0.33%MU+0.17%JPM-1.63%WMT-0.51%AMD+2.08%V-0.17%XOM+2.30%JNJ-0.76%ASMLa-1.02%0700.HK+1.90%MA-0.28%INTC+1.31%ABBV+0.55%1398.HK-2.09%CSCO+0.37%CVX+1.83%BAC-0.93%ORCL-0.72%COST-1.44%KO-1.28%DELL+2.75%CAT-0.49%0005.HK-3.21%HSBA.L-2.33%PG+0.43%UNH-1.65%LRCX-2.49%AP2d-2.07%AMAT-1.48%1816.HK-0.46%3988.HK-2.13%NFLX-2.89%GE-2.74%MS-2.44%0857.HK+0.60%HD-1.77%PM-0.21%0939.HK-2.83%USDJPY+0.99%NZDUSD-0.95%CHFJPY+0.77%USDTHB+0.69%CADJPY+0.68%NZDCHF-0.64%NZDCAD-0.64%AUDUSD-0.61%GBPJPY+0.57%GBPNZD+0.56%EURUSD-0.51%EURJPY+0.45%EURNZD+0.44%GBPTRY+0.41%AUDJPY+0.40%GBPUSD-0.39%NOKJPY+0.36%PLNJPY+0.36%AUDNZD+0.35%GBPHKD+0.32%USDCAD+0.31%USDCHF+0.31%SGDJPY+0.29%AUDCHF-0.29%GBPMXN-0.28%AUDCAD-0.28%USDSEK+0.27%NZDMXN-0.25%USDTRY+0.25%EURCAD-0.23%GBPZAR-0.21%GBPAUD+0.20%EURSEK+0.19%USDSGD+0.19%EURCHF-0.18%USDILS+0.16%NZDSGD-0.16%USDNOK+0.12%USDPLN+0.12%EURAUD+0.11%EURSGD+0.11%GBPCHF-0.11%USDMXN+0.10%EURCZK+0.10%EURGBP-0.09%AUDDKK-0.09%GBPCAD-0.08%USDDKK+0.08%CHFNOK-0.08%EURZAR-0.08%CHFSEK+0.08%EURHKD-0.07%USDCNH+0.06%AUDNOK-0.05%NZDJPY+0.04%EURCNH-0.04%EURPLN+0.04%USDCOP-0.04%EURNOK+0.04%USDHKD+0.02%GBPSGD-0.02%AUDSGD+0.02%CADCHF-0.01%CHFSGD-0.01%EURDKK0.00%USDZAR0.00%USOIL+3.10%COCOA-2.83%COFFEE-1.85%UKOIL+1.68%W1+1.58%S1+1.25%SUGAR-0.99%C1+0.90%XNGUSD+0.72%HG1+0.65%COTTON-0.38%XPTUSD+0.32%BTCUSD-2.21%ETHUSD-3.65%USDTUSD-0.04%XRPUSD-2.20%SOLUSD-3.13%TRXUSDT-0.56%ZECUSDT-3.66%DOGEUSD-2.25%XMRUSDT-0.17%LINKUSD-2.06%XLMUSD+0.16%BCHUSDT-0.81%UNIUSD-2.14%LTCUSD-2.49%HBARUSDT+0.68%TONUSD+26.79%SUIUSD-2.34%TAOUSDT-2.86%AAVEUSD-2.78%DOTUSDT-1.61%ICPUSDT-7.65%ONDOUSDT-3.29%WLDUSDT-1.82%ARBUSDT+11.73%ATOMUSDT-1.63%JUPUSDT-4.30%INJUSDT-10.16%STXUSDT-3.11%FETUSDT-4.35%PYTHUSDT-3.67%TIAUSDT-5.58%SEIUSDT-2.47%IMXUSDT-1.00%OPUSDT-1.70%GRTUSDT-3.41%POLUSDT+1.03%WIFUSDT-4.27%IOTAUSDT-5.85%AXSUSDT-2.84%FARTCOINUSDT-1.05%EOSUSDT-4.33%DYDXUSDT-5.90%ORDIUSDT-1.80%GALAUSDT-1.47%NOTUSDT-2.37%RONINUSDT-14.59%NVDA+0.52%AAPL-0.70%GOOGL-1.40%MSFT-0.90%AMZN-1.60%TSM-1.08%SPCX-2.59%META+0.01%AVGO-1.47%TSLA+0.48%SKHY-1.20%BRK-B+0.03%LLY+0.33%MU+0.17%JPM-1.63%WMT-0.51%AMD+2.08%V-0.17%XOM+2.30%JNJ-0.76%ASMLa-1.02%0700.HK+1.90%MA-0.28%INTC+1.31%ABBV+0.55%1398.HK-2.09%CSCO+0.37%CVX+1.83%BAC-0.93%ORCL-0.72%COST-1.44%KO-1.28%DELL+2.75%CAT-0.49%0005.HK-3.21%HSBA.L-2.33%PG+0.43%UNH-1.65%LRCX-2.49%AP2d-2.07%AMAT-1.48%1816.HK-0.46%3988.HK-2.13%NFLX-2.89%GE-2.74%MS-2.44%0857.HK+0.60%HD-1.77%PM-0.21%0939.HK-2.83%USDJPY+0.99%NZDUSD-0.95%CHFJPY+0.77%USDTHB+0.69%CADJPY+0.68%NZDCHF-0.64%NZDCAD-0.64%AUDUSD-0.61%GBPJPY+0.57%GBPNZD+0.56%EURUSD-0.51%EURJPY+0.45%EURNZD+0.44%GBPTRY+0.41%AUDJPY+0.40%GBPUSD-0.39%NOKJPY+0.36%PLNJPY+0.36%AUDNZD+0.35%GBPHKD+0.32%USDCAD+0.31%USDCHF+0.31%SGDJPY+0.29%AUDCHF-0.29%GBPMXN-0.28%AUDCAD-0.28%USDSEK+0.27%NZDMXN-0.25%USDTRY+0.25%EURCAD-0.23%GBPZAR-0.21%GBPAUD+0.20%EURSEK+0.19%USDSGD+0.19%EURCHF-0.18%USDILS+0.16%NZDSGD-0.16%USDNOK+0.12%USDPLN+0.12%EURAUD+0.11%EURSGD+0.11%GBPCHF-0.11%USDMXN+0.10%EURCZK+0.10%EURGBP-0.09%AUDDKK-0.09%GBPCAD-0.08%USDDKK+0.08%CHFNOK-0.08%EURZAR-0.08%CHFSEK+0.08%EURHKD-0.07%USDCNH+0.06%AUDNOK-0.05%NZDJPY+0.04%EURCNH-0.04%EURPLN+0.04%USDCOP-0.04%EURNOK+0.04%USDHKD+0.02%GBPSGD-0.02%AUDSGD+0.02%CADCHF-0.01%CHFSGD-0.01%EURDKK0.00%USDZAR0.00%USOIL+3.10%COCOA-2.83%COFFEE-1.85%UKOIL+1.68%W1+1.58%S1+1.25%SUGAR-0.99%C1+0.90%XNGUSD+0.72%HG1+0.65%COTTON-0.38%XPTUSD+0.32%BTCUSD-2.21%ETHUSD-3.65%USDTUSD-0.04%XRPUSD-2.20%SOLUSD-3.13%TRXUSDT-0.56%ZECUSDT-3.66%DOGEUSD-2.25%XMRUSDT-0.17%LINKUSD-2.06%XLMUSD+0.16%BCHUSDT-0.81%UNIUSD-2.14%LTCUSD-2.49%HBARUSDT+0.68%TONUSD+26.79%SUIUSD-2.34%TAOUSDT-2.86%AAVEUSD-2.78%DOTUSDT-1.61%ICPUSDT-7.65%ONDOUSDT-3.29%WLDUSDT-1.82%ARBUSDT+11.73%ATOMUSDT-1.63%JUPUSDT-4.30%INJUSDT-10.16%STXUSDT-3.11%FETUSDT-4.35%PYTHUSDT-3.67%TIAUSDT-5.58%SEIUSDT-2.47%IMXUSDT-1.00%OPUSDT-1.70%GRTUSDT-3.41%POLUSDT+1.03%WIFUSDT-4.27%IOTAUSDT-5.85%AXSUSDT-2.84%FARTCOINUSDT-1.05%EOSUSDT-4.33%DYDXUSDT-5.90%ORDIUSDT-1.80%GALAUSDT-1.47%NOTUSDT-2.37%RONINUSDT-14.59%
UP

UroGen Pharma Ltd. (URGN)

NASDAQ • Healthcare

$42.64
+$0.32 (+0.8%)
Market open

Last close at September 14, 2026 at 20:00 UTC

Open$42.36
Previous Close$42.64
Day Range$41.65 - $43.72
Avg. Volume (3M)833.7K
Market Cap$2B
52 Week Range
$15.86$50.81
Next EarningsIn 51 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$72.4M100%
Gross Profitminus cost of goods$65.8M91%
Operating Incomeminus R&D and overhead$111K0%

In plain terms: out of every $100 in revenue, UroGen Pharma Ltd. currently loses $20.

Fundamentals & Financials

Revenue (TTM)
$188.7M
Net Income (TTM)
-$97.6M
EPS (TTM)
-$1.98
ROA (TTM)
-38.65%
Current Ratio
3.8

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-4.2%Q1 2026-$0.54
+16.1%Q2 2026-$0.47
-5.7%Q3 2026-$0.28
Next

Nov 5

in 51 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -5.7%

UroGen Pharma’s revenue topped consensus but EPS trailed expectations in the second fiscal quarter of 2026, reported August 5, 2026, as sales growth outpaced the bottom-line improvement. Revenue rose 199.2% to about $72.5 million (up from about $24.2 million a year ago) and topped the $63.5 million estimate (+14%), while EPS of -$0.28 trailed the -$0.27 estimate (difference -$0.02) but improved from -$1.05 a year ago. Profitability was reflected in gross profit of roughly $65.9 million alongside gross margin of ~91%, and net income narrowed to a loss of about $14.4 million (from a loss of roughly $49.9 million a year ago), a +71.3% year-over-year change. Cash generation remained negative, with negative operating cash flow of about $33.0 million. For the next period, consensus calls for EPS of $0.10 on revenue of $90.6 million.

View full earnings history

About UroGen Pharma Ltd.

UroGen Pharma Ltd. develops and commercializes treatments for urothelial and specialty cancers. Listed on NASDAQ as URGN, it operates as a biotechnology company built around localized drug delivery and cancer therapeutics, and it generated $109.8 million of revenue in FY2025.

Name
UroGen Pharma Ltd.
CEO
Elizabeth Barrett
Website
www.urogen.com
Industry
Healthcare
Year Founded
2004
Employees
300

Today's Snapshot

AI-generated

URGN opened 1.4% above yesterday's close, while its sector was flat. UroGen reported faster launch progress for Zusduri, its bladder-cancer drug, at an investor conference.

Trading Volume

Below 10d avg (641.5K)

62.7K

vs S&P 500 Today

Underperforming Market

-2.50%

Updated: September 15, 2026 at 14:58 UTC

Technical Indicators

3 Buy1 Neutral4 Sell
URGN registers a Neutral technical stance because short- and medium-term indicators are bearish while longer-term averages and volume muddy the picture. The price is below the 10/20/50-day averages but remains above the 100/200-day levels, and momentum readings are mixed with Stochastic/Williams showing buy signals while CCI and MACD lean negative. ADX is low, indicating a weak trend, ATR is elevated suggesting notable intraday swings, and on-balance volume is positive, hinting at some underlying accumulation. The pivot sits above the current price, offering resistance. Technical takeaway: neutral—conflicting short- versus long-term signals, weak trend strength and mixed volume.
All signals
  • EMA (5 indicators)$31.14 - $43.94
    Sell
  • RSI (14)39.85
    Neutral
  • Stochastic %K (14, 3, 3)11.10
    Buy
  • MACD Level (12, 26)-0.42
    Sell

Peers & Related Assets

TNGXTango Therapeutics, Inc.
$24.54+3.2%
NRIXNurix Therapeutics, Inc.
$25.52+1.7%
KODKodiak Sciences Inc.
$33.14+0.8%
XNCRXencor, Inc.
$24.53+0.5%
ANABAnaptysBio, Inc.
$54.11+0.5%
PHATPhathom Pharmaceuticals, Inc.
$8.68+3.8%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.